Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 배상철 | - |
dc.date.accessioned | 2018-11-16T06:57:10Z | - |
dc.date.available | 2018-11-16T06:57:10Z | - |
dc.date.issued | 2016-09 | - |
dc.identifier.citation | MODERN RHEUMATOLOGY, v. 26, NO. 5, Page. 651-661 | en_US |
dc.identifier.issn | 1439-7595 | - |
dc.identifier.issn | 1439-7609 | - |
dc.identifier.uri | https://www.tandfonline.com/doi/full/10.3109/14397595.2015.1123349 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/80489 | - |
dc.description.abstract | Objectives: To investigate the efficacy and safety of etanercept (ETN) in patients with rheumatoid arthritis (RA) with moderate disease activity and the possibility to discontinue ETN after achieving remission. Methods: Multicenter, randomized, and open-label study was conducted in Japan and Korea. RA patients (disease duration ˂5 years) with moderate disease activity despite methotrexate (MTX) treatment were allocated to either MTX or ETN + MTX (Period 1) for 12 months. Patients who achieved sustained remission defined as DAS28 ˂2.6 at both 6 and 12 months in the ETN + MTX group, were randomized to either continue or discontinue ETN for 12 months (Period 2). Results: A total of 222 patients were enrolled in Period 1 and clinical remission was achieved in 106/ 157 (67.5%) and 5/ 28 (17.9%) patients in the ETN + MTX and MTX groups, respectively. In Period 2, sixty-seven patients were randomized and finally 28/ 32 (87.5%) and 15/ 28 (53.6%) patients who continued or discontinued ETN maintained clinical remission. Baseline disease activity and the presence of comorbid diseases influenced the maintenance of remission after ETN discontinuation. Conclusions: ETN + MTX was efficient for RA patients with moderate disease activity into remission. After achieving sustained remission, a half of the patients who discontinued ETN could maintain remission for 1 year. | en_US |
dc.description.sponsorship | The authors thank the TAP in Japan and CMIC in Korea for support of this clinical study. The institutions and names of the chief investigators of the ENCOURAGE study group are listed below: (1) Institute of Rheumatology Tokyo Women's Medical University, Hisashi Yamanaka (2) Keio University Hospital, Tsutomu Takeuchi (3) School of Medicine University of Occupational & Environmental Health, Yoshiya Tanaka (4) Asahikawa Medical University Hospital, Yuichi Makino (5) Taihakusakura Hospital (Munakata Yasuhiko Clinic), Yasuhiko Munakata (6) Tohoku kouseinenkin Hospital (Tohoku Pharmaceutical University Hospital), Takao Kodera (7) Tohoku University Hospital, Tomonori Ishii (8) Nishinarita Clinic, Makoto Nishinarita (9) Saitama Medical Center, Koichi Amano (10) Asahi Chuou Hospital, Itsuo Iwamoto (11) Chiba University Hospital, Kei Ikeda (12) Chibaken Saiseikai Narashino Hospital, Yasushi Nawata (13) Itabashi Chuo Medical Center, Hitomi Haraoka (14) Tokyo Women's Medical University Medical Center East, Katsuaki Kanbe (15) Juntendo University Hospital, Yoshinari Takasaki (16) Showa University Hospital, Tsuyoshi Kasama (17) Kawasaki Municipal Hospital, Yutaka Okano (18) Kawasaki RA & IM Clinic, Norihiko Koido (19) Kitasato University Hospital, Shunsei Hirohata (20) Miyagi Clinic, Kenichi Miyagi (21) St. Joseph's Hospital, Yoichi Ichikawa (22) Yokohama City University Hospital, Yoshiaki Ishigatsubo (23) Yokohama Minami Kyosai Hospital, Shouhei Nagaoka (24) Nishioka Clinic for Rheumatic Diseases and Allergic Diseases, Yuichi Nishioka (25) Shinonoi General Hospital, Sadahiro Suzuki (26) Nagano Red Cross Hospital, Toshihisa Kanamono (27) Nagoya City University Hospital, Taio Naniwa (28) Japanese Red Cross Kyoto Daiichi Hospital, Wataru Fukuda (29) Kyoto University Hospital, Tsuneyo Mimori (30) Kyoto Prefectural University of Medicine, Yutaka Kawahito (31) Osaka University Hospital, Tetsuya Tomita (32) Hyogo College of Medicine, Hajime Sano (33) Higami Hospital, Kenshi Higami (34) Matsuyama Red Cross Hospital, Shinichi Mizuki (35) Shono Rheumatism Clinic, Eisuke Shono (36) Sugioka Memorial Hospital, Ryuji Nagamine (37) Sasebo Chuo Hospital, Yukitaka Ueki (38) Shiminnomori Hospital, Toshihiko Hidaka (39) Yonsei University Health, System, Soo-Kon Lee (40) Hanyang University, Sang-Cheol Bae | en_US |
dc.language.iso | en | en_US |
dc.publisher | SPRINGER | en_US |
dc.subject | Clinical trial | en_US |
dc.subject | Discontinuation | en_US |
dc.subject | Etanercept | en_US |
dc.subject | Remission | en_US |
dc.subject | Rheumatoid arthritis | en_US |
dc.title | Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study | en_US |
dc.type | Article | en_US |
dc.relation.no | 5 | - |
dc.relation.volume | 26 | - |
dc.identifier.doi | 10.3109/14397595.2015.1123349 | - |
dc.relation.page | 651-661 | - |
dc.relation.journal | MODERN RHEUMATOLOGY | - |
dc.contributor.googleauthor | Yamanaka, Hisashi | - |
dc.contributor.googleauthor | Nagaoka, Shouhei | - |
dc.contributor.googleauthor | Lee, Soo-Kon | - |
dc.contributor.googleauthor | Bae, Sang-Cheol | - |
dc.contributor.googleauthor | Kasama, Tsuyoshi | - |
dc.contributor.googleauthor | Kobayashi, Hitomi | - |
dc.contributor.googleauthor | Nishioka, Yuichi | - |
dc.contributor.googleauthor | Ueki, Yukitaka | - |
dc.contributor.googleauthor | Seto, Yohei | - |
dc.contributor.googleauthor | Nishinarita, Makoto | - |
dc.relation.code | 2016005338 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | scbae | - |
dc.identifier.orcid | http://orcid.org/0000-0003-4658-1093 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.